Identifying antibodies in patients with myasthenia gravis provides invaluable insights that can help tailor treatments and improve patient outcomes. PHOENIX, Arizona—Recent advances in myasthenia ...
Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...
Hosted on MSN
Emerging Myasthenia Gravis Treatments
The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...
Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile. Freimer was an author on 5 abstracts presented at the ...
Diagnosis of generalized myasthenia gravis involves clinical symptoms, serologic markers, and electrodiagnostic studies, with AChR and MuSK autoantibodies being key indicators. Differentiating ...
ATLANTA, Oct. 17, 2023 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ® (zilucoplan) has been approved by the U.S. Food and Drug ...
The available drugs for generalized myasthenia gravis address only patients whose disease exhibits a particular biological profile. The FDA has approved a new UCB drug that encompasses those covered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results